RAPP
Rapport Therapeutics, Inc. Common Stock
NASDAQ · USHealthcareBiotechnology
$40.21-5.65%
Price as of Jul 20, 2026
RAPP capital
Rapport Therapeutics, Inc. Common Stock capital & dividend
Leverage, liquidity, debt coverage and shareholder-distribution metrics.
Leverage
- Debt / equity
- 0.02x
- Net debt / equity
- -0.14x
- Debt / assets
- 0.02x
- Debt / EBITDA
- -0.09x
- Net debt / EBITDA
- 0.57x
Liquidity & coverage
- Current ratio
- 27.08x
- Quick ratio
- 27.08x
- Cash ratio
- 26.64x
- Interest coverage
- —
- EBITDA / interest
- —
- Working capital
- $466.8M
Cash & dividend
- FCF / debt
- -7.47x
- Cash flow / debt
- -7.43x
- Dividend per share
- —
- Dividend yield
- —
- Dividend growth 1y
- —
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.